课题基金 / 基金详情

Gene-Therapy Clinical-Trial Candidate Screening for Ophthalmology enabled by Low-Cost Widefield Fundus Camera

Gene-Therapy Clinical-Trial Candidate Screening for Ophthalmology enabled by Low-Cost Widefield Fundus Camera
低成本宽场眼底相机支持眼科基因治疗临床试验候选人筛选
批准号:
10076107
负责人:
金额:
$6.28万
依托单位国家:
英国
项目类别:
Grant for R&D
财政年份:
2023
资助国家:
英国
项目状态:
已结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
An extremely exciting application of engineering biology is the recent development and advancement of cellular and gene therapy treatments. Here, we are proposing a disruptive monitoring device to significantly reduce and streamline the selection process for clinical trial patients in gene-therapy treatments targeting Ophthalmological applications.Gene-therapy based Ophthalmic treatments offer significant promise for preventing and reversing blindness in a range of untreatable disorders. This encompasses more common disorders such as Dry Age-Related Macular Disorder and Diabetic Retinopathy (most common old-age and working age causes of blindness in the developed world) to rarer diseases such as Choroideremia. A key challenge to the realisation of these gene-therapy treatments is identifying suitable clinical-trial patients to collect sufficient data to approve their use. This is the engineering biology challenge our project shall overcome.Screening for suitable clinical-trial patients is a major challenge. Even in resource-rich developed countries, there is typically insufficient bandwidth of trained Ophthalmic expertise in the healthcare system to enable reliable screening of eye-care. This issue is exacerbated for the selection of clinical-trial patients; selection requires identifying suitable candidates in appropriate time-window and then continuously monitoring their progression.These approaches present significant limitations which Cambridge Vision Technology shall obviate with this project. We are developing a low-cost imaging device which does not require the expertise of a trained medical professional. Effectively, we are proposing a solution to automate and dramatically reduce the economic cost of the clinical-trial candidate selection process for gene-therapies. This would provide a key piece of infrastructure and be transformative in enabling the development of a host of gene-therapies for Ophthalmological applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金